Market Cap 19.28M
Revenue (ttm) 0.00
Net Income (ttm) -6.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 17,300
Avg Vol 65,930
Day's Range N/A - N/A
Shares Out 7.04M
Stochastic %K 46%
Beta 0.07
Analysts Strong Sell
Price Target $11.00

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
AllPenniesNoDividends
AllPenniesNoDividends Oct. 27 at 8:45 PM
$EDSA is that a slight amount of excitement I’m starting to sense on this board? Something must be wrong here… $1.50 incoming 😆
0 · Reply
EireTrader
EireTrader Oct. 27 at 7:25 PM
$EDSA .. A point to consider. 104 patients ties in nicely with change of endpoint ( see PRs and Clinical Trials ) That leaves well over a year for the next cohort at 28 Day Mortality. Maybe another 100 patients 🤔
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 27 at 2:56 PM
$EDSA 24 sites now activated for the JB trial - last update posted today
2 · Reply
EireTrader
EireTrader Oct. 26 at 4:54 PM
$EDSA ... I wonder is this the plan...
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 25 at 11:06 PM
$EDSA these faggots had the article pulled....fuck them in their Canadian assholes
1 · Reply
EireTrader
EireTrader Oct. 25 at 12:01 PM
$EDSA ... Discussion thread for comments / input / nEDgative comments. A) P3 data in hand since before August.(Based on deadline for Abstract submission at CHEST) B) Government grant amended with likely sight of data. Includes intriguing reference to other EB05 Projects. C) Presented at CHEST under Embargo. D) Reporting restrictions lift on 31st October. Possibilities to get us going... I think an EUA application in Canada, with funding now in place for manufacturing, is a real possibility.
2 · Reply
pausiloy
pausiloy Oct. 25 at 4:08 AM
$EDSA which will happen first? EB01 partnership / EB05 buyout / EB06 P2 trial
1 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Oct. 24 at 9:25 PM
$NEM $GDX $EDSA WE ARE FAMOUS!! Check out the featured quote! https://stocktwits.com/news-articles/markets/equity/why-did-gold-miner-newmont-s-stock-fall-over-5-after-hours-today/cLGJJFSR3rw
0 · Reply
EireTrader
EireTrader Oct. 24 at 8:18 AM
$EDSA .... It is worth noting that the original P2 Substudy results, had a Cox's Hazard Model reduction in the risk of dying of 84% when compared to placebo. These results from a larger study of 104 patients appears consistent, even with a different endpoint.
1 · Reply
pausiloy
pausiloy Oct. 24 at 4:45 AM
$EDSA at least we know EB05 has very postitive result in covid p3 on critical patients, and it is backed up by BARDA now, i am bullish and will keep adding though sp is way underperformed and par is keep diluting
0 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 2 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results


Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 5 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results


Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 7 months ago

Edesa Biotech Announces Chief Financial Officer Transition


Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 9 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results


Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 11 months ago

Edesa Biotech Reports Fiscal Year 2024 Results


Edesa Biotech Announces Upcoming Conference Schedule

Oct 21, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech Announces Upcoming Conference Schedule


Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results


Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results


Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results


Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results


Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit


Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split


Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results


Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role


Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name


Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results


Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Edesa Biotech to Participate in Swiss Biotech Day


Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results


FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate


Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results


Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Sep 7, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment


Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Aug 12, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results


AllPenniesNoDividends
AllPenniesNoDividends Oct. 27 at 8:45 PM
$EDSA is that a slight amount of excitement I’m starting to sense on this board? Something must be wrong here… $1.50 incoming 😆
0 · Reply
EireTrader
EireTrader Oct. 27 at 7:25 PM
$EDSA .. A point to consider. 104 patients ties in nicely with change of endpoint ( see PRs and Clinical Trials ) That leaves well over a year for the next cohort at 28 Day Mortality. Maybe another 100 patients 🤔
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 27 at 2:56 PM
$EDSA 24 sites now activated for the JB trial - last update posted today
2 · Reply
EireTrader
EireTrader Oct. 26 at 4:54 PM
$EDSA ... I wonder is this the plan...
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 25 at 11:06 PM
$EDSA these faggots had the article pulled....fuck them in their Canadian assholes
1 · Reply
EireTrader
EireTrader Oct. 25 at 12:01 PM
$EDSA ... Discussion thread for comments / input / nEDgative comments. A) P3 data in hand since before August.(Based on deadline for Abstract submission at CHEST) B) Government grant amended with likely sight of data. Includes intriguing reference to other EB05 Projects. C) Presented at CHEST under Embargo. D) Reporting restrictions lift on 31st October. Possibilities to get us going... I think an EUA application in Canada, with funding now in place for manufacturing, is a real possibility.
2 · Reply
pausiloy
pausiloy Oct. 25 at 4:08 AM
$EDSA which will happen first? EB01 partnership / EB05 buyout / EB06 P2 trial
1 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Oct. 24 at 9:25 PM
$NEM $GDX $EDSA WE ARE FAMOUS!! Check out the featured quote! https://stocktwits.com/news-articles/markets/equity/why-did-gold-miner-newmont-s-stock-fall-over-5-after-hours-today/cLGJJFSR3rw
0 · Reply
EireTrader
EireTrader Oct. 24 at 8:18 AM
$EDSA .... It is worth noting that the original P2 Substudy results, had a Cox's Hazard Model reduction in the risk of dying of 84% when compared to placebo. These results from a larger study of 104 patients appears consistent, even with a different endpoint.
1 · Reply
pausiloy
pausiloy Oct. 24 at 4:45 AM
$EDSA at least we know EB05 has very postitive result in covid p3 on critical patients, and it is backed up by BARDA now, i am bullish and will keep adding though sp is way underperformed and par is keep diluting
0 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Oct. 23 at 7:14 PM
$EDSA I can still see it in the USA: https://www.pulmonologyadvisor.com/reports/ards-in-covid-19-paridiprubart-may-reduce-imv/
0 · Reply
EireTrader
EireTrader Oct. 23 at 4:18 PM
$EDSA Gary's Appraisal
0 · Reply
Bullforlyfe
Bullforlyfe Oct. 23 at 3:47 PM
$EDSA Jesus... @pausiloy You're trying your best to ensure Gary avoids the shower rooms for the next several years. Give the man a break - they tried to take it down in the US/Canada
0 · Reply
pausiloy
pausiloy Oct. 23 at 2:53 PM
$EDSA repost "Cox regression analysis suggested an 88% higher rate for paridiprubart vs placebo in achieving a WCSS reduction of at least 2 points" https://www.pulmonologyadvisor.com/reports/ards-in-covid-19-paridiprubart-may-reduce-imv/
1 · Reply
EireTrader
EireTrader Oct. 23 at 1:39 PM
$EDSA ... Story taken Down Pausiloy
2 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 23 at 1:34 AM
$EDSA Publication Rules: Publication is contingent upon in-person presentation at the meeting. Presenting authors who have not accepted to present by the deadline provided in the invitation and have yet to reach out to us regarding any delay may have their submission(s) withdrawn from presentation and publication. Accepted submissions for CHEST 2025 can not be published elsewhere before October 31, 2025.
1 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Oct. 22 at 10:54 PM
$EDSA I wonder if this recent data got revealed at the end of last month somewhere we missed leading to that random spike over $4
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 22 at 10:41 PM
$EDSA Schrodingers paridiprubart
0 · Reply
AllPenniesNoDividends
AllPenniesNoDividends Oct. 22 at 10:12 PM
$EDSA Oddest company ever.. IMO they just keep their head down and will eventually just take a buyout when the time is right… this is Par’s typical play on his private companies he’s ran and he has a huge stake in this one too. Every time they announce almost anything the get dumped on, so just hold the cards close to the chest and take the buyout when the price is right. Not the most exciting, but that’s the only thing that would make any sense or else Par would’ve been dumping shares long ago IMO
2 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 22 at 6:45 PM
$EDSA My take....P3 data now unblinded. Meaningful, statistical significant clinical benefit in the sickest patients. Cox regression HR, while not stat sig, shows time to improvement in the EB05 dosed patients. 28 day mortality likely not stat sig, hence why not presented, but trial was very small so understandable. Between this and the P2 substudy there's enough to somewhat "derisk" the EB05 program. For one, I don't think it has the blockbuster potential we may have initially envisioned, but since ARDS is high complexity with high mortality, any therapy that can improve clinical outcomes with a good safety profile can likely eventually get approval. The BARDA P2 will give us more insight and has hard endpoints. BARDA I think will fund a P3, and EB05 will likely be part of that. Long road ahead but just enough to keep me encouraged. Neutral.
0 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 22 at 5:14 PM
$EDSA Any normal company would have pr'd their participation in the conference along with the data, commentary, and a copy of the abstract once available. One has to ask themselves why Edesa goes to great lengths to obscure and obfuscate information from market participants. This is not a one off occurrence. It's another item in a long on going pattern of murky disclosure. Crazy to think it took them 3 years to get an approved trial protocol and enroll 100 patients. Clear as day why the suspended the trial. What a waste tho.....tens of millions burned for nothing. Also the primary outcome measure as of 2023 is mortality at 28 days........so what's up with that? That's why this company is a joke. I have zero hope for recouping any of my investment. Only an acquisition or major partnership would turn the tide....but with inconclusive data no one is going to bite.
1 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 22 at 2:51 PM
$EDSA Welp, that was short lived. Gonna take more than that to convince mr. market. Timber.....! 2027/2028....trapped for another 2 year minimum.
0 · Reply